Loading
A phase 3 trial of Cemiplimab in cutaneous squamous cell carcinoma, run by Regeneron Pharmaceuticals, now recruiting.
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06585410 by Regeneron Pharmaceuticals, with 369 participants planned, started 2025-01-02 and due to reach its primary completion in 2030-05-03. Interventions recorded: Cemiplimab, Standard of care. Conditions listed: Cutaneous Squamous Cell Carcinoma (CSCC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced cutaneous squamous cell carcinoma, Cemiplimab, Cutaneous squamous cell carcinoma, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/